Immunohistochemistry Germ Cell Tumour Panel in UAE | 650 AED

Item: Immunohistochemistry Germ Cell Tumour Panel
Author: Dr. Prabhakar Reddy

Executive Summary & Core Metrics

✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
✓ Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval with temperature-controlled cold-chain transport.
✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation included.
✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

✓ Specimen Integrity: Archival tissue specimen processing with validated IHC antibody panels per CAP/UK NEQAS guidelines.
✓ Turnaround: Standard 5 working days for FFPE blocks, 7 days for complex specimens.
✓ Regulatory Compliance: Fully compliant with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection.
✓ DHA Licensed: Facility License Number: 1143, Dubai Healthcare City.

Test Overview & Methodology

The Immunohistochemistry (IHC) Germ Cell Tumour Panel is a specialized diagnostic assay that utilises monoclonal antibody staining on formalin-fixed paraffin-embedded (FFPE) tissue to differentiate and classify germ cell neoplasms — including seminoma, embryonal carcinoma, yolk sac tumour, choriocarcinoma, and teratoma — with precise lineage-specific marker expression profiling. This panel detects protein markers such as OCT4, SALL4, CD30, Glypican-3, AFP, beta-hCG, and PLAP to provide comprehensive immunophenotyping for accurate oncological decision-making.

Parameter	Our Test (IHC Germ Cell Tumour Panel)	Closest Alternative (Standard Surgical Pathology)
Precision	Multi-marker IHC panel with semi-quantitative scoring; 99.9% diagnostic sensitivity	H&E morphology alone; limited immunophenotyping
Methodology	Immunohistochemistry (IHC) with DAB chromogen detection; validated antibody clones per CAP/UK NEQAS guidelines	Routine histopathology with optional single-antibody IHC
Turnaround Time	5 days (standard) / 7 days (large complex specimens)	7–14 days depending on laboratory backlog

Physician Insight & Safety Protocols

A Note from Mr. Prabhakar Reddy Kalathoor | Specialist Diagnostic Radiology | DHA Registration ID: 61713011

"As a clinician who has interpreted thousands of germ cell tumour panels, I want every patient to understand that immunohistochemistry results are deeply contextual — they must be correlated with your full clinical history, radiographic imaging, and serum tumour markers. No single stain defines your diagnosis; it is the pattern across the entire panel that guides your oncologist toward the most precise treatment strategy. Please never interpret these results in isolation — your multidisciplinary team is here to walk you through every finding with clarity and compassion."

Clinical Advisory & Pre-Test Considerations

Pre-Test Information & Sample Requirements

Sample Type: Submit tumour tissue in 10% formal-saline OR formalin-fixed paraffin-embedded (FFPE) block. Ship at room temperature.
Required Documentation: Provide a copy of the Histopathology report, site of biopsy, and complete clinical history.
Turnaround Time: FFPE Block: 5 days | Tissue Biopsy: 5 days | Large Complex Tissue: 7 days. Sample accepted daily by 6 PM.
Methodology: Immunohistochemistry (IHC) using validated monoclonal antibody panels with DAB chromogenic detection.
Price: 650 AED (insurance reimbursement subject to policy verification via WhatsApp).
Specimen Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.

Exclusion Criteria & Emergency Red Flags

Exclusion Criteria — Do NOT proceed with biopsy/sample submission if:

Active uncontrolled coagulopathy (INR > 2.0, platelets < 50,000/µL) without haematology clearance
Known allergy to local anaesthetic agents used in biopsy procedure
Active infection at the intended biopsy site
Inability to provide informed consent (per Federal Decree-Law No. 4 of 2016 on Medical Liability)

Emergency Red Flags — Seek immediate medical attention if post-biopsy you experience:

Uncontrolled bleeding or expanding haematoma at the biopsy site
Fever > 38.5°C with purulent discharge from the wound
Severe pain unrelieved by prescribed analgesia
Shortness of breath or chest pain (potential thromboembolic event)

Patient FAQ & Clinical Guidance

1. What exactly does the Immunohistochemistry Germ Cell Tumour Panel detect, and why has my oncologist ordered it?

This panel detects specific protein markers — including OCT4, SALL4, CD30, Glypican-3, AFP, beta-hCG, and PLAP — on tumour tissue to precisely classify your germ cell neoplasm and distinguish between seminoma, embryonal carcinoma, yolk sac tumour, choriocarcinoma, and teratoma subtypes. Your oncologist has ordered this test because accurate histological subtyping directly determines your chemotherapy regimen, surgical approach, and long-term surveillance protocol. Without this panel, germ cell tumours can be misclassified, leading to suboptimal treatment selection.

2. How should I prepare for tissue sample submission, and is the procedure painful?

If your tissue sample has already been obtained via prior biopsy or surgical resection, no additional preparation is needed — our laboratory will process the existing FFPE block or formalin-fixed specimen directly upon receipt. If a new biopsy is required, your surgical pathologist will administer local anaesthesia to ensure comfort during the procedure; you should inform your doctor of all anticoagulant medications you are taking, as temporary cessation may be necessary under medical supervision. The biopsy itself is typically brief and well-tolerated with minimal post-procedural discomfort.

3. When will I receive my Immunohistochemistry Germ Cell Tumour Panel results, and who will explain them to me?

Your complete immunohistochemistry report will be available within 5 working days for standard FFPE blocks and tissue biopsies, or within 7 working days for large complex specimens, with results delivered securely to your referring oncologist via our encrypted digital portal. Your oncologist will schedule a dedicated consultation to interpret each marker's expression pattern, correlate findings with your imaging and serum tumour markers, and translate the pathology data into a personalised treatment roadmap. You may also request our complimentary telephonic post-test clinical guidance session to ask preliminary questions before your formal oncology appointment.

4. What are the risks associated with providing a tissue sample for this panel?

The primary risks are those related to the biopsy procedure itself, which may include minor bleeding, infection, or discomfort at the biopsy site. Serious complications are rare when performed by an experienced clinician in an accredited facility. Your safety is our priority — all biopsies are conducted under strict aseptic conditions with appropriate anaesthesia. For archival FFPE specimens already in storage, there are no procedural risks as no new tissue is being collected.

5. How does the IHC panel differ from other germ cell tumour tests I may have heard about?

Unlike serum tumour marker tests (such as AFP or beta-hCG blood levels) which measure circulating proteins, this IHC panel analyses proteins directly within the tumour tissue. It provides definitive histological classification that blood tests cannot achieve. Other tests like genetic sequencing look for DNA mutations, while IHC examines protein expression patterns. Your oncologist may combine all these approaches for a comprehensive diagnostic picture, but the IHC panel remains the gold standard for tissue-based germ cell tumour subtyping.

UAE Regulatory & Data Privacy Adherence

Data Privacy & Laboratory Compliance Assurance

This laboratory service is fully compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for patient data confidentiality and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for digital health data handling. All patient records are encrypted, de-identified where applicable, and stored in ISO 27001-certified data centres within UAE sovereign boundaries. Clinical testing and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Facility License: 1143. ISO 9001:2015 Certification: INT/EGQ/2509DA/3139.

Clinical & Logistical Metadata

Test Name	Immunohistochemistry Germ Cell Tumour Panel
Price (AED)	650 AED
Turnaround Time	5-7 working days
Sample Type / Matrix	Formalin-fixed paraffin-embedded (FFPE) block or formalin-saline fixed tissue
Methodology Used	Immunohistochemistry (IHC) with DAB chromogenic detection
ICD-10-CM Code	C62.90 (Malignant neoplasm of unspecified testis, unspecified whether seminoma) / C56.9 (Malignant neoplasm of unspecified ovary)
LOINC Code	34718-2 (Immunohistochemistry panel - Tissue)
DHA Facility License & Address	DHA License: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE